JRCT ID: jRCT2080225146
Registered date:30/03/2020
LET for the prevention of CMV infection/disease in pediatric HSCT recipients
Basic Information
Recruitment status | completed |
---|---|
Health condition(s) or Problem(s) studied | Pediatric participants receiving HSCT at risk for CMV infection and/or disease |
Date of first enrollment | 08/05/2020 |
Target sample size | 5 |
Countries of recruitment | United States,Turkiye,Spain,Poland,Mexico,Israel,Germany,France,Colombia,Australia |
Study type | Interventional |
Intervention(s) | Receive LET once a day from the day of enrollment (Day 1, within 28 days post-transplant) through 14 weeks (~100 days) post-transplant |
Outcome(s)
Primary Outcome | AUC0-24, Cmax (for participants receiving oral formulation), Ceoi (for participants receiving IV formulation), and Ctrough |
---|---|
Secondary Outcome | Adverse Events (AEs) AEs Resulting in Study Medication Discontinuation Clinically significant CMV infection through Week 14 (~100 days) post-transplant and through Week 24 (~6 months) post-transplant Score on a palatability scale. |
Key inclusion & exclusion criteria
Age minimum | >= |
---|---|
Age maximum | < 18age old |
Gender | Both |
Include criteria | - All participants 12 to <18 years old must have documented positive CMV serostatus(CMV IgG seropositive)for the recipient(R+)within 90 days prior to enrollment. Participants from birth to <12 years old must have documented positive CMV serostatus(CMV IgG seropositive)for the recipient(R+)within 90 days prior to enrollment and/or the donor(D+); the donor serostatus should be documented within 1 year prior to enrollment. - Is the recipient of a first allogeneic HSCT(bone marrow, peripheral blood stem cell, or cord blood transplant). - Has undetectable CMV DNA from a plasma or whole blood sample collected within 5 days prior to enrollment. - Is within 28 days post-HSCT at the time of enrollment. - Females are not pregnant, not breastfeeding, and is not a woman of childbearing potential(WOCBP); or is a WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 28 days after the last dose of study intervention. - Participants from 2 to <18 years of age must not be on concomitant Cyclosporin A(CsA), and must be able to take LET tablets or the oral granules(either by mouth or via G tube/NG tube), provided the participant does not have a condition that may interfere with the absorption of oral medication(e.g. vomiting, diarrhea, or a malabsorptive condition)from the day of enrollment until the intensive PK sampling is completed in these participants. - For participants 2 <12 years old their weight should be at least 10 kg; for participants from birth to <2 years old their weight should be at least 2.5 kg and less than or equal to 15 kg at the time of enrollment. |
Exclude criteria | - Has received a previous allogeneic HSCT(Note: receipt of a previous autologous HSCT is acceptable). - Has a history of CMV end-organ disease within 6 months prior to enrollment. - Has evidence of CMV viremia at any time from either signing of the ICF or the HSCT procedure, whichever is earlier, until the time of enrollment. - Has suspected or known hypersensitivity to active or inactive ingredients of LET formulations. - Has severe hepatic insufficiency within 5 days prior to enrollment. - Is a)on renal replacement therapy(eg, hemodialysis, peritoneal dialysis)OR b)has end-stage renal impairment. - Has both moderate hepatic insufficiency and moderate-to-severe renal insufficiency. - Has an uncontrolled infection on the day of enrollment. - Requires mechanical ventilation or is hemodynamically unstable at the time of enrollment. - Has a documented positive result for a human immunodeficiency virus antibody(HIVAb)test at any time prior to enrollment, or for hepatitis C virus antibody(HCV-Ab)with detectable HCV RNA, or hepatitis B surface antigen(HBsAg)within 90 days prior to enrollment. - Has active solid tumor malignancies with the exception of localized basal cell or squamous cell skin cancer or the condition under treatment(e.g. lymphomas). - Has a preexisting cardiac condition a)for which the patient is currently being treated or b)which required hospitalization within the last 6 months or c)that may be expected to recur during the course of the trial. - Has received within 7 days prior to screening any of the following: ganciclovir; valganciclovir; foscarnet; acyclovir; valacyclovir; famciclovir. - Has received within 30 days prior to screening of any of the following: cidofovir; CMV immunoglobulin; any investigational CMV antiviral agent/biologic therapy; Rifampin and other strong inducers(such as phenytoin, carbamazepine, St John's wort(Hypericum perforatum), rifabutin and phenobarbital)and moderate inducers such as nafcillin, thioridazine, modafinil and bosentan. - Has received LET at any time prior to enrollment in this study. - Is currently participating or has participated in a study with an unapproved investigational compound or device within 28 days, or 5X half-life of the investigational compound(excluding monoclonal antibodies), whichever is longer, of initial dosing in this study. - Has previously participated in this study or any other study involving LET. - Has previously participated or is currently participating in any study involving administration of a CMV vaccine or another CMV investigational agent, or is planning to participate in a study of a CMV vaccine or another CMV investigational agent during the course of this study. - Is pregnant or expecting to conceive, is breastfeeding, or plans to breastfeed from the time of consent through 28 days after the last dose of study intervention. - Is expecting to donate eggs starting from the time of consent through 28 days after the last dose of study intervention. - Has clinically relevant drug or alcohol abuse within 12 months of screening that may interfere with participant treatment, assessment, or compliance with the protocol, as assessed by the investigator. |
Related Information
Primary Sponsor | MSD K.K. |
---|---|
Secondary Sponsor | |
Source(s) of Monetary Support | |
Secondary ID(s) | NCT03940586,JapicCTI-205242 |
Contact
Public contact | |
Name | MSDJRCT inquiry mailbox |
Address | KITANOMARU SQUARE,1-13-12,Kudan-kita,Chiyoda-ku,Tokyo 102-8667,Japan |
Telephone | +81-3-6272-1957 |
msdjrct@merck.com | |
Affiliation | MSD K.K. |
Scientific contact | |
Name | Yoshiyuki Tanaka |
Address | KITANOMARU SQUARE,1-13-12,Kudan-kita,Chiyoda-ku,Tokyo 102-8667,Japan |
Telephone | +81-3-6272-1957 |
msdjrct@merck.com | |
Affiliation | MSD K.K. |